enGene (ENGN) Chief Strategy & Ops Officer receives 195,000-share option grant

Rhea-AI Filing Summary

enGene Holdings Inc. granted a stock option to Chief Strategy & Ops Officer Alexander Julian Nichols covering 195,000 common shares on January 30, 2026.

The option has an exercise price of $9.53 per share and expires on January 30, 2036. It was granted at no cost to the reporting person and vests in substantially equal monthly installments over 48 months, conditioned on continued service. After this grant, Nichols beneficially owns 195,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nichols Alexander Julian

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT A8 H4R 2P1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enGene Holdings Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy & Ops. Ofc

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.53	01/30/2026		A		195,000		(1)	01/30/2036	Common Shares	195,000	$0	195,000	D

Explanation of Responses:

1. This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.

	/s/ Alexander J. Nichols	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did enGene Holdings Inc. (ENGN) disclose in this Form 4 filing?

enGene Holdings Inc. disclosed a stock option grant to executive Alexander Julian Nichols for 195,000 common shares. The option was awarded on January 30, 2026, and is documented as a derivative security transaction under Section 16 reporting requirements.

Who is the insider involved in this ENGN Form 4 and what is their role?

The insider is Alexander Julian Nichols, who serves as enGene Holdings Inc.’s Chief Strategy & Ops Officer. He is not listed as a director or 10% owner, but as a reporting officer receiving equity-based compensation through a stock option grant.

How many shares are covered by the stock option reported for ENGN’s executive?

The stock option reported for enGene’s executive covers 195,000 common shares. This entire amount is reflected as derivative securities beneficially owned directly by Alexander Julian Nichols following the transaction recorded in the Form 4 filing.

What are the key terms of the ENGN stock option grant, including exercise price and expiration?

The enGene stock option carries an exercise price of $9.53 per share and expires on January 30, 2036. It is structured as a right to buy common shares, giving the executive long-dated potential ownership if exercised.

How does the ENGN stock option for Alexander Nichols vest over time?

The option vests monthly in substantially equal amounts over 48 months, subject to Alexander Nichols’ continued service. This means the grant becomes exercisable gradually, aligning ongoing vesting with his tenure at enGene Holdings Inc.

Is the ENGN stock option grant to Alexander Nichols a purchase or a cost-free award?

The Form 4 shows the option grant with a price of $0 for the derivative security itself, indicating it is a cost-free award at grant. Any future cost would arise only if he chooses to exercise at the $9.53 strike price.